<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03721302</url>
  </required_header>
  <id_info>
    <org_study_id>NeoOBS 001</org_study_id>
    <nct_id>NCT03721302</nct_id>
  </id_info>
  <brief_title>NeoAMR Observational Study in Neonatal Sepsis</brief_title>
  <official_title>A Prospective, Multinational, Observational, Cohort Study Sepsis in Hospitalised Neonates in Areas With High Endemic Levels of Antimicrobial Resistance.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Drugs for Neglected Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St George's, University of London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PENTA Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universiteit Antwerpen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Drugs for Neglected Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multinational, multicentre, observational cohort study of neonatal sepsis in&#xD;
      partner institutions. The cohort study will be designed to evaluate health care utilization&#xD;
      and current clinical practice and to assess risk factors for and outcomes of babies with&#xD;
      neonatal sepsis (culture-negative and culture-positive).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. NeoSEPSIS: Consecutive hospitalized babies with neonatal sepsis will be recruited and&#xD;
           followed up until discharge from hospital or death (for a maximum of 28 days). A minimal&#xD;
           neonatal sepsis dataset will determine (i) clinical presentations, associated features&#xD;
           and risk factors (for example prematurity, SGA (small for gestational age)), (ii) rates&#xD;
           of culture-positivity among babies with sepsis, (iii) current empirical treatment&#xD;
           approaches (antimicrobials selected, dose, etc) (iv) outcomes of sepsis, including&#xD;
           death, need for intensive care interventions and recurrence of sepsis during the&#xD;
           follow-up period. Microbiological samples will be taken from sterile sites, blood and&#xD;
           CSF, as clinically indicated and will be processed locally.&#xD;
&#xD;
        2. NeoBSI: Consecutive babies with positive blood/CSF cultures and sepsis will be&#xD;
           recruited. Patient inclusion will be based on identification of relevant specified&#xD;
           bacteria from blood / CSF cultures. In addition to the data collected for NeoSEPSIS,&#xD;
           information will be collected on the isolates and their antimicrobial susceptibility&#xD;
           patterns.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 16, 2018</start_date>
  <completion_date type="Actual">February 29, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality Rate</measure>
    <time_frame>28 days</time_frame>
    <description>To estimate mortality rates in hospitalised infants less than 60 days of age who are being treated for significant sepsis (where significant is defined as presenting with 2 or more of the signs /symptoms listed in the inclusion criteria).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the microbiological epidemiology, including antimicrobial susceptibility and resistance mechanisms, in infants with positive blood and/or cerebrospinal fluid culture</measure>
    <time_frame>28 days</time_frame>
    <description>The incidence of culture positive and culture negative sepsis (both bloodstream and CSF isolates)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">3202</enrollment>
  <condition>Neonatal SEPSIS</condition>
  <arm_group>
    <arm_group_label>Main Study Clinical Sepsis</arm_group_label>
    <description>Clinical and Antimicrobial Assessments</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microbiology Sub study</arm_group_label>
    <description>Clinical and Antimicrobial Assessments</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Main study clinical sepsis</intervention_name>
    <description>No intervention-Observational study</description>
    <arm_group_label>Main Study Clinical Sepsis</arm_group_label>
    <arm_group_label>Microbiology Sub study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Microbiology sub study</intervention_name>
    <description>Analysis of Bacterial isolates</description>
    <arm_group_label>Microbiology Sub study</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Microbiological isolates&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalized Babies with significant sepsis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  In-patient in the hospital (NNU (Neonatal unit) or paediatric ward) of one of the&#xD;
             partner institutions&#xD;
&#xD;
               -  Age &lt;60 days of age&#xD;
&#xD;
               -  Clinical suspicion of a new episode of sepsis (as defined below)** together with&#xD;
                  planned treatment with IV antibiotics OR new episode of confirmed bacterial&#xD;
                  meningitis^ OR new episode of infection in which a Carbapenem-resistant organism&#xD;
                  (CRO) is isolated from blood culture OR new episode of infection in which a&#xD;
                  candida species is isolated from blood culture&#xD;
&#xD;
               -  Informed consent from parent / guardian&#xD;
&#xD;
               -  Willingness to provide location information and to be contacted at 28 days from&#xD;
                  start of antibiotic treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Previously enrolled in this study, unless readmitted and re-started on antibiotics&#xD;
             before the 28 day follow-up limit is reached&#xD;
&#xD;
               -  Enrollment in any interventional trial&#xD;
&#xD;
               -  A serious, non-infective co-morbidity (other than prematurity), anticipated to&#xD;
                  cause death within 72 hours&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>60 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mike Sharland</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. George's Hospital, University of London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dhaka Shishu Hospital</name>
      <address>
        <city>Dhaka</city>
        <country>Bangladesh</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FCM da Santa Casa de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Children Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Obstetrics and Gynecology Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shenzhen Children Hospital</name>
      <address>
        <city>Shenzhen</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hippokration Hospital</name>
      <address>
        <city>Thessaloníki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Edward Memorial Hospital and Seth Gordhandas Sunderdas Medical College</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lady Hardinge Medical College</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER)</name>
      <address>
        <city>Pondicherry</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bambino Gesu Hospital</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KEMRI/Wellcome Trust Research Programme</name>
      <address>
        <city>Kilifi</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tygerberg Hospital</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Maxeke</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chris Hani Baragwanath Academic Hospital</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Sirikit National Institute of Child Health</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiang Rai Prachanukroh Hospital</name>
      <address>
        <city>Chang Rai</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mulago Hospital</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vietnam National Hospital of Paediatrics</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bangladesh</country>
    <country>Brazil</country>
    <country>China</country>
    <country>Greece</country>
    <country>India</country>
    <country>Italy</country>
    <country>Kenya</country>
    <country>South Africa</country>
    <country>Thailand</country>
    <country>Uganda</country>
    <country>Vietnam</country>
  </location_countries>
  <reference>
    <citation>Folgori L, Ellis SJ, Bielicki JA, Heath PT, Sharland M, Balasegaram M. Tackling antimicrobial resistance in neonatal sepsis. Lancet Glob Health. 2017 Nov;5(11):e1066-e1068. doi: 10.1016/S2214-109X(17)30362-5.</citation>
    <PMID>29025624</PMID>
  </reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 4, 2018</study_first_submitted>
  <study_first_submitted_qc>October 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2018</study_first_posted>
  <last_update_submitted>August 17, 2020</last_update_submitted>
  <last_update_submitted_qc>August 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Neonatal Sepsis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

